The U.S. National Institutes of Health devoted $20 million to develop an HIV drug-delivering intravaginal ring. The design of a successful ring is a priority in HIV research, and the sustained release of drugs the ring offers could eventually play a crucial role in HIV prevention in the developing world.
Researchers have designed a novel suppository for HIV antiretroviral delivery using the seaweed extract carrageenan. Almost half of the antiretroviral drug tenofovir diffused out of the delivery mechanism within the first two hours in an in vitro study testing the product in water, vaginal simulant fluid and semen simulant fluid.
The discovery of a new HIV antibody highlights the need to create vaccines with trimeric delivery systems that resemble those found naturally, said Mark Connors, the research team's principal investigator and chief of the HIV-Specific Immunity Section.
Looking back on data from old pediatric HIV vaccine trials, researchers have found that two vaccines studied in the 1990s elicited a specific antibody response that was unknown at the time to be associated with HIV protection.
In a finding that could help scientists develop better therapies against HIV, investigators at the University of California, Davis, have discovered how HIV hides out in reservoirs in the human gut to avoid eradication.
GlaxoSmithKline may be suffering from R&D setbacks, generic competition and corruption investigations in a dozen countries, but its HIV-oriented venture ViiV Healthcare is racking up new OKs. Friday, the company scored the FDA's blessing for a combo drug pegged at $5 billion in peak sales.
A new strategy that uses broadly neutralizing antibodies combined with a cocktail of viral-inducing compounds may be able to stop HIV from rebounding, according to researchers at Rockefeller University.
Researchers at the University of Washington have developed a medicated, electrospun fabric that could prevent HIV infections in women.
Without explaining why, AbbVie has decided not to appeal a court ruling that extended rights to gay jurors which materialized out of litigation it has been waging with GlaxoSmithKline over the pricing of an HIV med. But it is seldom a good idea for a pharma company to antagonize its patient base. And gay men make up a significant number of the patients on HIV drugs sold by the drugmaker.
The CRO unit of nonprofit researcher SRI International has paired up with NIH's National Institute of Allergy and Infectious Diseases, signing a $49 million contract to handle preclinical work on potential treatments for HIV.